Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydronidone Extension in CHB Liver Fibrosis
NCT05905172Phase 3Recruiting
- Sponsor
- Gyre Pharmaceuticals
- Start
- Aug 2023
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Liver Fibrosis (LF) and Chronic Hepatitis B (CHB) comparing Hydronidone group with Placebo group (2 arms). Primary endpoint: Cumulative incidence of clinical endpoint events at 5 years. Started Aug 2023; status: recruiting.
02
Drugs
hydronidone
03
Conditions
Liver Fibrosis (LF)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05905172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905172.